In summary, our data are the first, to our knowledge, powered to evaluate whether the routinely used and recommended dosing of sublingual misoprostol (600 μg) is non-inferior to oxytocin 10 IU for the outcome of PPH. This evidence concerns the gene OXT and pulmonary arterial hypertension.